BlackRock
TVRD

BlackRock’s Tvardi Therapeutics TVRD Stock Holding History

BlackRock’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.23M Sell
388,075
-2,925
-0.7% -$11.5K ﹤0.01% 4265
2025
Q4 		$1.68M Buy
391,000
+61,086
+19% +$547K ﹤0.01% 4172
2025
Q3 		$12.9M Buy
329,914
+62,039
+23% +$1.77M ﹤0.01% 3321
2025
Q2 		$6.25M Buy
267,875
+247,252
+1,199% +$5.85M ﹤0.01% 3665
2025
Q1 		$314K Hold
20,623
– – ﹤0.01% 4518
2024
Q4 		$379K Sell
20,623
-1
-0% -$11 ﹤0.01% 4490
2024
Q3 		$229K Sell
20,624
-62
-0.3% -$727 ﹤0.01% 4501
2024
Q2 		$192K Sell
20,686
-74,352
-78% -$1.77M ﹤0.01% 4558
2024
Q1 		$3.11M Sell
95,038
-3,691
-4% -$95.7K ﹤0.01% 3850
2023
Q4 		$2.64M Sell
98,729
-4,274
-4% -$177K ﹤0.01% 3932
2023
Q3 		$6.23M Buy
103,003
+171
+0.2% +$16K ﹤0.01% 3583
2023
Q2 		$10.5M Sell
102,832
-108,354
-51% -$14.9M ﹤0.01% 3395
2023
Q1 		$37.3M Sell
211,186
-3,612
-2% -$1.21M ﹤0.01% 2644
2022
Q4 		$83M Buy
214,798
+4,179
+2% +$1.59M ﹤0.01% 2123
2022
Q3 		$71M Buy
210,619
+6,375
+3% +$2.31M ﹤0.01% 2190
2022
Q2 		$67.1M Buy
204,244
+4,602
+2% +$1.61M ﹤0.01% 2290
2022
Q1 		$87.3M Sell
199,642
-334
-0.2% -$137K ﹤0.01% 2220
2021
Q4 		$87.7M Buy
199,976
+2,604
+1% +$1.31M ﹤0.01% 2293
2021
Q3 		$110M Sell
197,372
-5,297
-3% -$2.66M ﹤0.01% 2154
2021
Q2 		$104M Buy
202,669
+100,253
+98% +$63.5M ﹤0.01% 2217
2021
Q1 		$80M Buy
102,416
+1,520
+2% +$1.04M ﹤0.01% 2321
2020
Q4 		$55M Sell
100,896
-1,741
-2% -$913K ﹤0.01% 2414
2020
Q3 		$47M Sell
102,637
-2,123
-2% -$1.23M ﹤0.01% 2343
2020
Q2 		$64.5M Buy
104,760
+7,587
+8% +$4.19M ﹤0.01% 2111
2020
Q1 		$46.2M Sell
97,173
-1,336
-1% -$726K ﹤0.01% 2098
2019
Q4 		$57.1M Sell
98,509
-79
-0.1% -$55.4K ﹤0.01% 2277
2019
Q3 		$64.9M Buy
98,588
+19,017
+24% +$15.8M ﹤0.01% 2138
2019
Q2 		$61.6M Buy
79,571
+2,729
+4% +$1.92M ﹤0.01% 2210
2019
Q1 		$54.3M Sell
76,842
-953
-1% -$570K ﹤0.01% 2226
2018
Q4 		$36.4M Buy
77,795
+1,181
+2% +$762K ﹤0.01% 2410
2018
Q3 		$66.1M Buy
76,614
+14,357
+23% +$10.4M ﹤0.01% 2226
2018
Q2 		$42.9M Buy
62,257
+2,246
+4% +$1.14M ﹤0.01% 2450
2018
Q1 		$26.7M Sell
60,011
-1,306
-2% -$633K ﹤0.01% 2607
2017
Q4 		$27M Buy
61,317
+12,482
+26% +$5.69M ﹤0.01% 2626
2017
Q3 		$24.1M Buy
48,835
+3,089
+7% +$1.55M ﹤0.01% 2694
2017
Q2 		$25.3M Buy
45,746
+6,521
+17% +$4.14M ﹤0.01% 2668
2017
Q1 		$26M Buy
39,225
+39,109
+33,715% +$20.9M ﹤0.01% 2611
2016
Q4 		$39K Buy
116
+7
+6% +$2.25K ﹤0.01% 3049
2016
Q3 		$33K Hold
109
– – ﹤0.01% 3137
2016
Q2 		$19K Buy
109
+82
+304% +$17.9K ﹤0.01% 3283
2016
Q1 		$6K Buy
+27
New +$8.06K ﹤0.01% 3340

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock's TVRD Position: Q1 2026 in Review

BlackRock reduced its Tvardi Therapeutics (TVRD) stake by 0.75% in Q1 2026, selling an estimated $11.5K and leaving 388,075 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #4265.

BlackRock first reported a position in TVRD in Q1 2016 and has held it in 41 quarters since. The position peaked at $110M in Q3 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • BlackRock held 388,075 shares of Tvardi Therapeutics worth $1.23M as of Q1 2026.
  • BlackRock sold 2,925 Tvardi Therapeutics shares in Q1 2026, an estimated $11.5K.
  • Tvardi Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4265 holding.
  • BlackRock first reported a position in Tvardi Therapeutics in Q1 2016 and has held it in 41 quarters since.
  • BlackRock's Tvardi Therapeutics position peaked at $110M in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.